Market News & Trends
Croda Invests in SiSaf’s Novel Bio-Courier Technology
Croda International Plc and SiSaf Ltd recently announced an exciting new strategic partnership. Croda, the name behind high-performance ingredients and technologies that are relied on by industries and consumers everywhere, has agreed a commercial arrangement with SiSaf, a pioneering UK-based biopharmaceutical company.
Microfluidic Modulation Spectroscopy (MMS) For Protein Therapeutic Drug Analysis
Automated, high sensitivity spectroscopic analyses for the development, formulation and manufacture of biotherapeutics are now available thanks to RedShiftBio’s new AQS3pro protein characterization platform. The system is based on Microfluidic Modulation Spectroscopy (MMS) technology. Read this application note to learn about how MMS characterizes higher order protein structures, the mechanisms of protein stability, aggregation, protein similarity and quantitation.
ABITEC Corporation & DKSH Announce Specialty Lipid Distribution Agreement
ABITEC Corporation, a global manufacturer of specialty lipids, has executed a multi-year agreement with distribution partner DKSH to market and sell its ingredients into select…
Translate Bio Announces Closing of Collaboration & Licensing Agreement with Sanofi Pasteur
Translate Bio recently announced the closing of a previously announced research collaboration and licensing agreement with Sanofi Pasteur to develop mRNA vaccines for up to…
WuXi Biologics & Immune Pharmaceuticals Announce Late-Phase Development & Manufacturing Partnership
WuXi Biologics and Immune Pharmaceuticals recently announced a development and manufacturing agreement for the production of bertilimumab, Immune’s first-in-class anti-eotaxin-1 monoclonal antibody. Bertilimumab is designed…
FDA Grants Fast-Track Designation to Aclaris Therapeutics’ Investigational JAK Inhibitor
Aclaris Therapeutics, Inc. recently announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Aclaris’ investigational topical Janus Kinase (JAK) 1/3…
Hemispherx Files Positive Safety Report on Intranasal Use of Ampligen in Combination With FluMist Influenza Vaccine
Hemispherx Biopharma, Inc. recently announced the filing of a clinical study report on AMP-600, a Phase I/II trial of intranasal Ampligen in combination with FluMist…
Aurin Biotech Awarded US Patent for Cancer Drug
Aurin Biotech’s ATAC, a drug which has successfully halted the growth of cancerous tumors, was recently awarded a patent (10,004,707 B2) by the United States…
Catalent Biologics Adopts Berkeley Lights’ Beacon Optofluidic Platform
Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics, and consumer health products, and Berkeley Lights, Inc.…
Axovant Announces Global Licensing Agreement With Benitec Biopharma
Axovant Sciences recently announced it has licensed exclusive global rights to an investigational Silence-and-Replace gene therapy program from Benitec Biopharma for the treatment of oculopharyngeal…
Zynerba Pharmaceuticals Initiates CONNECT-FX, a Pivotal Clinical Trial
Zynerba Pharmaceuticals, Inc. recently announced the initiation of a multi-national, randomized, double blind placebo controlled Clinical study of Cannabidiol (CBD) in Children and Adolescents with…
Endocyte & ITM Announce Long-Term Supply Agreement
Endocyte, Inc. and ITM Isotopen Technologien München AG recently announced that ITM´s subsidiary, Isotope Technologies Garching GmbH (ITG), and Endocyte have signed a long-term global…
iBio Establishes Strategic Commercial Relationship with CC-Pharming Ltd.
iBio, Inc. recently announced the commencement of a strategic commercial relationship with CC-Pharming Ltd. of Beijing, China for joint development of products and manufacturing facilities…
Codexis Doses First Subjects in Phase 1a Trial; Triggers Milestone
Codexis, Inc. recently announced it has dosed the first subjects in a first-in-human Phase 1a dose-escalation trial with CDX-6114, its orally administered enzyme therapeutic being…
Eisai & Biogen Announce Positive Topline Results
Eisai Co., Ltd. and Biogen Inc. recently announced positive topline results from the Phase II study with BAN2401, an anti-amyloid beta protofibril antibody, in 856…
Integrated Partnerships Paired With Innovative Approaches Are a Key to Success
As we come to learn more about the human body, the dynamics of the industry must react accordingly. A primary example of this is the fact that the dominating blockbuster drug model that was paramount in the industry until a couple of years ago is no longer valid……
Pfenex Receives Milestone From Merck
Pfenex Inc. recently announced the receipt of a milestone payment from Merck associated with the initiation of the first Phase 3 clinical study of (V114), an investigational polyvalent conjugate vaccine for the prevention of pneumococcal disease.
Immatics Enters Strategic Partnership With Genmab
Immatics Biotechnologies GmbH recently announced it has entered into a research collaboration and license agreement with Genmab A/S to develop next-generation, T-cell engaging bispecific immunotherapies targeting multiple cancer indications.
Gerresheimer Acquires Sensile Medical
With the acquisition of Sensile Medical AG, Switzerland under a recent share purchase agreement, Gerresheimer is extending its business model in the direction of an Original Equipment Manufacturer (OEM) for drug delivery platforms with digital and electronic capabilities for pharmaceutical and biopharmaceutical customers.
BioCanCell Announces Completion of $23-Million Financing
BioCanCell Ltd. recently announced it has completed a $22.9-million PIPE financing round. The financing was led by Shavit Capital, with investors from the US, Israel, and…
